2/3
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Low
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
1/9
10:58 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.
Medium
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.
1/9
08:13 am
rnac
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]
1/9
08:04 am
rnac
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Medium
Report
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
1/6
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
12/18
04:36 pm
rnac
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]
Low
Report
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]
12/18
04:05 pm
rnac
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Low
Report
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
11/20
01:33 pm
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:07 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
11/14
08:26 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.
11/8
07:41 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
11/6
07:00 am
rnac
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update